These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30853081)

  • 21. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?
    Jen YM; Lin YS; Su WF; Hsu WL; Hwang JM; Chao HL; Liu DW; Chen CM; Lin HY; Wu CJ; Chang LP; Shueng PW
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):14-22. PubMed ID: 12182970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma.
    Chan OS; Sze HC; Lee MC; Chan LL; Chang AT; Lee SW; Hung WM; Lee AW; Ng WT
    Head Neck; 2017 Mar; 39(3):533-540. PubMed ID: 27898191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma: an evaluation of response and toxicity.
    Lu JJ; Shakespeare TP; Thiagarajan A; Zhang X; Liang L; Tan S
    Laryngoscope; 2005 May; 115(5):806-10. PubMed ID: 15867644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
    Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
    Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
    Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
    BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma.
    Tian YM; Guan Y; Xiao WW; Zeng L; Liu S; Lu TX; Zhao C; Han F
    Head Neck; 2016 Feb; 38(2):225-31. PubMed ID: 25244494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy.
    Tian YM; Huang WZ; Yuan X; Bai L; Zhao C; Han F
    Oncotarget; 2017 Jun; 8(26):43450-43457. PubMed ID: 28427216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy.
    Hsin CH; Chen TH; Liang KL; Tseng HC; Liu WS
    Laryngoscope; 2013 Sep; 123(9):2148-53. PubMed ID: 23835775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Locoregionally advanced nasopharyngeal carcinoma in childhood and adolescence: Analysis of 95 patients treated with combined chemotherapy and intensity-modulated radiotherapy.
    Guo Q; Cui X; Lin S; Lin J; Pan J
    Head Neck; 2016 Apr; 38 Suppl 1():E665-72. PubMed ID: 25867086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
    Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
    BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
    Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
    Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J
    BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma.
    Lu JJ; Kong L; Shakespeare TP; Loh KS; Zhang Q; Tan KS; Lee KM
    Oral Oncol; 2008 Jul; 44(7):703-9. PubMed ID: 18061528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: an evaluation of long-term outcome.
    Thiagarajan A; Lin K; Tiong CE; Tan LK; Loh TK; Goh BC; Lu JJ
    Laryngoscope; 2006 Jun; 116(6):938-43. PubMed ID: 16735885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
    Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
    Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
    Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
    Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: A meta-analysis.
    Leong YH; Soon YY; Lee KM; Wong LC; Tham IWK; Ho FCH
    Head Neck; 2018 Mar; 40(3):622-631. PubMed ID: 29130584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China.
    Zhao LN; Zhou B; Shi M; Wang JH; Xiao F; Xu M; Luo SQ; Xue Y; Li JP; Tan LN
    Oral Oncol; 2012 Sep; 48(9):864-9. PubMed ID: 22445296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of nasopharyngeal carcinoma using simultaneous modulated accelerated radiation therapy via helical tomotherapy: a phase II study.
    Du L; Zhang XX; Feng LC; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
    Radiol Oncol; 2016 Jun; 50(2):218-25. PubMed ID: 27247555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.